Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
echinomycin
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Merck (MSD)
Drug class:
DNA intercalator, RNA synthesis inhibitor, HIF-1α inhibitor
Related drugs:
‹
daunorubicin (20)
aclarubicin (1)
mitoxantrone liposomal (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
lyso-thermosensitive liposomal doxorubicin (0)
2X-111 (0)
dactinomycin (8)
pirarubicin (1)
OVI-123 (0)
PM14 (0)
NP-ACT D (0)
PCS3117 (0)
BAY 872243 (0)
BMX-001 (0)
EZN-2968 (0)
PX-478 (0)
EP0057 (0)
SLM (0)
simmitecan (0)
daunorubicin (20)
aclarubicin (1)
mitoxantrone liposomal (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
lyso-thermosensitive liposomal doxorubicin (0)
2X-111 (0)
dactinomycin (8)
pirarubicin (1)
OVI-123 (0)
PM14 (0)
NP-ACT D (0)
PCS3117 (0)
BAY 872243 (0)
BMX-001 (0)
EZN-2968 (0)
PX-478 (0)
EP0057 (0)
SLM (0)
simmitecan (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.